# Institut Gustave Roussy

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/institut-gustave-roussy/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 72 |
| Citations | 7,716,755 |
| City | Villejuif |
| Country | FR |
| Description | Institut Gustave Roussy is a research organisation in Villejuif, FR. OpenAlex records 43,215 works and 7,716,755 citations for it. 7,662 researchers list it as their most recent affiliation. |
| Homepage | http://www.gustaveroussy.fr/en |
| OpenAlex ID | https://openalex.org/I2801843802 |
| Region | Île-de-France |
| Researchers | 7,662 |
| ROR ID | https://ror.org/0321g0743 |
| Type | facility |
| Works | 43,215 |

## University collaborators

Showing 10 of 20.

- [Inserm](https://scholariq.org/institutions/inserm/)
- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)
- [Université Paris-Sud](https://scholariq.org/institutions/universite-paris-sud/)
- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)
- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)
- [Angeles Clinic and Research Institute](https://scholariq.org/institutions/angeles-clinic-and-research-institute/)
- [Assistance Publique – Hôpitaux de Paris](https://scholariq.org/institutions/assistance-publique-hopitaux-de-paris/)
- [Princess Margaret Cancer Centre](https://scholariq.org/institutions/princess-margaret-cancer-centre/)
- [Université Paris Cité](https://scholariq.org/institutions/universite-paris-cite/)
- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

## University papers

Showing 12 of 43.

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-plus-octreotide-long-acting-repeatable-for-the-treatment-of-advanced/)
- [Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy](https://scholariq.org/papers/cancer-cell-autonomous-contribution-of-type-i-interferon-signaling-to-the/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.